Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Bispecific (CD20×CD3)
Epcoritamab
Epkinly · Epcor
Subcutaneous CD3×CD20 bispecific — renal risk is downstream of CRS and tumor lysis.
ModerateT-cell-engaging bispecific · approved 2023
Large B-cell lymphomaDiffuse large B-cell lymphomaFollicular lymphoma
Signature kidney injury
Prerenal / Hemodynamic AKI
No direct tubular signal. AKI is case-level and downstream of CRS (~50% any-grade, predominantly grade 1-2 with subcutaneous step-up dosing) and tumor lysis; renal incidence is not separately quantified — emerging data.
Source: Thieblemont et al., J Clin Oncol 2022 (EPCORE NHL-1)
Mechanism of kidney injury
Indirect, like other CD20×CD3 bispecifics. Cytokine release (IL-6/IFN-gamma/TNF) causes hypotension and capillary leak that reduce renal perfusion (prerenal AKI), and rapid tumor lysis can drive uric-acid/phosphate crystal nephropathy. Subcutaneous administration and step-up priming doses are intended to produce a slower cytokine rise and lower-grade CRS than intravenous engagers.
Clinical presentation
Creatinine rise with CRS (fever, hypotension, often within 24-48 h of the first full dose); tumor-lysis labs (hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia) in high-burden disease. Sediment is generally bland.
Onset
Early — during cycle 1 step-up dosing with CRS.
Reversibility
Reversible
Anticancer mechanism
Subcutaneous CD3×CD20 T-cell-engaging bispecific antibody that bridges CD3+ T cells to CD20+ malignant B cells, driving T-cell-mediated cytotoxicity. Approved for relapsed/refractory large B-cell lymphoma after two or more prior lines.
Management
Manage CRS with supportive care, tocilizumab and corticosteroids per grade; restore perfusion; correct tumor-lysis electrolytes; provide supportive AKI care including dialysis if severe.
Risk factors
- High/bulky tumor burden
- Rapidly proliferative lymphoma
- Volume depletion
- Pre-existing CKD
Prevention
- Step-up priming doses
- Corticosteroid premedication and CRS monitoring
- Tumor lysis prophylaxis (hydration, allopurinol/rasburicase)
- Volume optimization
Note · Renal data are emerging; direct nephrotoxicity has not been established. Risk is CRS/tumor-lysis mediated.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment defined; IgG bispecific exposure is not expected to depend on renal clearance. No dedicated data in severe impairment/ESKD.
Dialyzability & ESKD dosing
Not dialyzable (large IgG, reticuloendothelial catabolism). No supplemental dosing for HD/PD.
Differential diagnosis
Separate CRS-related prerenal AKI (fever, hypotension, fluid-responsive) from tumor lysis AKI (urate/phosphate, electrolyte signature) and the rare CRS-associated collapsing glomerulopathy seen on biopsy with T-cell engagers. Drug-intrinsic tubular injury is not an established mechanism.
Monitoring
- Creatinine and electrolytes (K, phosphate, uric acid, calcium) around each step-up dose
- CRS vital signs/inflammatory markers during the priming cycle
- Tumor lysis labs in high-burden disease during initial dosing
Key trials & series
- EPCORE NHL-1 / Thieblemont JCO 2022 (CRS ~50%, predominantly grade 1-2)
Clinical pearls
- Subcutaneous dosing softens the cytokine peak versus IV engagers, but CRS-driven prerenal AKI still clusters in cycle 1.
- Most AKI is fluid- and CRS-management responsive; reach for biopsy only if heavy proteinuria or an atypical course suggests glomerular disease.
- High tumor burden is the dominant modifiable risk — front-load tumor-lysis prophylaxis.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bispecific (cd20×cd3)s.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkEpcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.Thieblemont C et al. · J Clin Oncol 2022 · PMID 36548927Pivotal EPCORE NHL-1 expansion: CRS in ~50% (mostly grade 1-2). Basis for CRS-mediated renal risk.PMIDAcute Kidney Injury in Cancer Immunotherapy Recipients.Joseph A et al. · Cells 2022 · PMID 36552755Onconephrology review of CRS-, tumor-lysis- and infiltration-mediated AKI with bispecific T-cell engagers.PMIDCollapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report.Acharya R et al. · Kidney Med 2021 · PMID 34939018Collapsing glomerulopathy/AKI with CRS, including after a CD19xCD3 bispecific — illustrates the rare glomerular pattern.PMIDEmergencies in Hematology: Why, When and How I Treat?Duminuco A et al. · J Clin Med 2024 · PMID 39768494Tumor lysis and CRS with electrolyte derangement and AKI in the bispecific era.PMIDTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Howard SC et al. · Ann Hematol 2016 · PMID 26758269Systematic review of TLS risk across novel agents in hematologic malignancies.PMIDAnticancer Drug-Induced Acute Kidney Injury.Izzedine H et al. · Kidney Int Rep 2017 · PMID 29318217Onconephrology reference for prerenal/tumor-lysis AKI mechanisms.
Related agents
Other agents sharing the same signature kidney injury.